The Filing Desk

Rhythm Pharmaceuticals

RYTM · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

RYTM · Last close · November 13, 2026
$115.02
Value Rhythm Pharmaceuticals yourself

Rhythm Pharmaceuticals' revenue rose 45.8% to $190 million in fiscal 2025. Its operating margin was −101.2%, up from −204.0% a year earlier. Free cash flow was −$117 million. The diluted share count rose 6.5%.

RHYTHM PHARMACEUTICALS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001628280-26-012399 Updated
Revenue
$190M
45.8%
Operating margin
−101.2%
102.8 pts
Net income
−$196M
 
Free cash flow
−$117M
 
Return on equity
−244.4%
27.7 pts
Market cap
$7.9B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Rhythm Pharmaceuticals does

Rhythm Pharmaceuticals sells medicines for rare diseases that cause intense, constant hunger and severe obesity. These conditions trace to faults in the melanocortin-4 receptor (MC4R) pathway, a signaling system in the brain that helps control hunger and how the body uses energy.

Its one marketed product is IMCIVREE (setmelanotide). It is sold in the United States, the European Union, the United Kingdom, Canada and some other places for certain rare genetic obesity diseases, including Bardet-Biedl syndrome. The company makes money by selling this drug. It says it expects to launch IMCIVREE in the United States in 2026 for acquired hypothalamic obesity, which is weight gain caused by injury to part of the brain, if regulators approve it.

Rhythm is also testing two earlier-stage drugs in the same family: bivamelagon, taken by mouth, and RM-718, designed to be given once a week by injection. It holds worldwide rights to IMCIVREE and global rights to these two. It had 414 employees on February 1, 2026, including some in 11 countries outside North America.

Its biggest risks, as it describes them

  • It has a limited history selling drugs and has not yet earned significant revenue from them.
  • It may need to raise more funding, which may not be available on acceptable terms.
  • Its revenue interest financing agreement with Healthcare Royalty Partners could limit its cash and its choices.
  • Results from earlier trials may not predict later ones, and early data it announces may change.
  • The number of patients with each rare disease it targets is small and not precisely known.
From Rhythm Pharmaceuticals's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Rhythm Pharmaceuticals lost money in fiscal 2025: a net loss of $196 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments295333276321389
Debt incl. finance leases——106110108
Net debt (negative means net cash)——−170−211−281
Net debt to EBITDA—————
Debt to equity——0.6x5.0x0.8x
Interest coverage—−34.5x−13.3x−12.9x−9.3x
Current ratio7.1x8.9x5.6x3.2x4.4x
Quick ratio7.1x8.8x5.4x3.1x4.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Rhythm Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Rhythm Pharmaceuticals shares on the open market, and 9 insiders sold $36.4 million, $35.4 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 14, 2026David P MeekerPresident and CEO, DirectorSold plan50,000$102.67$5.1 millionForm 4
Aug 31, 2026Hunter C SmithChief Financial OfficerSold plan62,774$105.46$6.6 millionForm 4
Aug 13, 2026Jennifer Kayden LeeEVP, Head of North AmericaSold plan75,834$117.38$8.9 millionForm 4
Aug 13, 2026Alastair GarfieldChief Scientific OfficerSold plan7,763$117.57$912,697Form 4
Aug 13, 2026Joseph ShulmanChief Technical OfficerSold plan5,079$119.75$608,210Form 4
Aug 12, 2026Yann MazabraudEVP, Head of InternationalSold plan57,000$116.15$6.6 millionForm 4
Jun 22, 2026Lynn A. TetraultDirectorSold plan37,000$100.32$3.7 millionForm 4
May 15, 2026Christopher Paul GermanCorporate Controller & CAOSold4,643$92.21$428,131Form 4
Mar 4, 2026Christopher Paul GermanCorporate Controller & CAOSold5,614$89.56$502,790Form 4
Feb 19, 2026Hunter C SmithChief Financial OfficerSold plan4,385$101.26$444,009Form 4
Feb 17, 2026Hunter C SmithChief Financial OfficerSold plan3,569$101.38$361,813Form 4
Feb 12, 2026Hunter C SmithChief Financial OfficerSold plan1,592$98.23$156,378Form 4
The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—3 of 96 of 9
Rule of 4051.6%−19.4%−15.6%
Altman Z''−6.41−9.72−6.24
Accruals ratio−13.6%−40.5%−18.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets—FailPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score—3 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Rhythm Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Rhythm PharmaceuticalsFY2545.8%−101.2%−61.5%——6
Stoke TherapeuticsFY25404.5%−11.2%24.4%———Compare
Syndax PharmaceuticalsFY25627.8%−158.4%−187.5%———Compare
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
LiquidiaFY251,031.2%−32.5%−25.3%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000032477130190
Revenue growth——————649.5%227.6%68.1%45.8%
Gross profit—————32268117170
Research and development20235010990104109135238167
Operating income−26−32−78−146−137−170−179−184−266−192
Net income−26−34−74−141−134−70−181−185−261−196
Diluted EPS (US$)−2.85−2.83−2.39−3.86−3.04−1.40−3.47−3.20−4.34−3.11
Diluted shares (millions)10133136445052586165
Cash flow
Cash from operations−23−30−62−123−122−146−173−136−114−116
Capital expenditure1013000001
Free cash flow−24−30−63−126−122−146−174−136−114−117
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation12612182120334067
Balance sheet at fiscal year end
Cash and short-term investments10148252292173295333276321389
Debt incl. finance leases———————106110108
Total assets12152260308187330382333392480
Total liabilities5714282045118163228210
Shareholders' equity−3314524628116628426417022139
Margins and ratios
Gross margin—————81.0%91.0%88.0%89.7%89.7%
Operating margin—————−5,391.9%−757.9%−238.1%−204.0%−101.2%
Net margin—————−2,207.1%−766.2%−238.5%−200.3%−103.6%
Free cash flow margin—————−4,642.9%−734.9%−175.9%−87.5%−61.5%
Rule of 40 (growth + FCF margin)——————−85.4%51.6%−19.4%−15.6%
Return on capital——————————
Return on equity—−60.1%−37.9%−53.4%−59.9%−30.9%−66.0%−85.1%−272.2%−244.4%
Return on assets—−41.1%−36.0%−49.5%−54.1%−26.9%−50.9%−51.6%−71.9%−45.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Rhythm Pharmaceuticals' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Rhythm Pharmaceuticals.